ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Brain"

  • Abstract Number: 0870 • ACR Convergence 2021

    Blood Brain Barrier Integrity and Brain Imaging Patterns in Patients with SLE

    Shiran Aharon1, Dafna Ben-Bashat2, Orna Aizenstein3, Moran Artzi4, Mark Berman5, Victoria Furer6, Marina Anouk7, Yael Lahat8, Jonathan Wollman9, Ofir Elalouf9, Ari Polachek10 and Daphna Paran11, 1Wohl Institute of Advanced Imaging, Tel-Aviv Sourasky Medical Center, Sagol School of Neuroscience, Sackler Faculty of Medicine, Tel-Aviv, Israel, 2Wohl Institute of Advanced Imaging, Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel, 3Department of Neuroradiology Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel, 4Wohl Institute of Advanced Imaging, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, 5Department of Rheumatology , Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel Aviv, Israel, 6Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 7Department of Rheumatology, Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel, 8Department of Rheumatology , Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel, 9Tel Aviv Medical Center, Herzliya, Israel, 10Sourasky Medical Center, Petah-Tikva, Israel, 11Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel

    Background/Purpose: The pathogenesis of neuropsychiatric SLE (NPSLE) has not been fully elucidated. Recent evidence suggests impaired blood brain barrier (BBB) integrity as a possible mechanism…
  • Abstract Number: 0410 • ACR Convergence 2020

    Exploring Gene Expression Profile of Primary Central Nervous System Vasculitis

    Carlo Salvarani1, Robert Brown2, Jonas Paludo2, Stefania Croci3, Stephen Ansell4, Caterina Giannini2, Joseph Parisi2, Kenneth Warrington2 and Gene Hunder2, 1Azienda USL-IRCCS di Reggio Emilia e Università di Modena e Reggio Emilia, Reggio Emilia, Italy, 2Mayo Clinic, Rochester, MN, 3Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, 4Mayo Clinic, Rochester

    Background/Purpose: Primary CNS vasculitis (PCNSV) is an uncommon and poorly understood disease that affects the brain and spinal cord. It includes heterogeneous  histopathological patterns,  clinical…
  • Abstract Number: 0978 • ACR Convergence 2020

    Border-associated Macrophages Drive Recruitment of Immune Cells into the Choroid Plexus in Mice with Neuropsychiatric Lupus

    Erica Moore1 and Chaim Putterman1, 1Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: Neuropsychiatric manifestations are observed in 20-40% of systemic lupus erythematosus patients, including cognitive deficits and affective behaviors such as anxiety and depression. Neuropsychiatric lupus…
  • Abstract Number: 1747 • ACR Convergence 2020

    Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Multi-center, Randomized, Double-blind, Placebo-controlled Trial (PreCePRA)

    Juergen Rech1, Hannah Schenker2, Koray Tascilar1, Melanie Hagen2, Arnd Kleyer1, David Simon1, Larissa Valor Mendez2, Verena Schoenau3, Jutta Prade4, Marina Sergeeva4, Mageshvar Sulvakumar5, Sandra Strobelt4, Laura Konerth4, Frank Behrens6, Christoph Baerwald7, Stephanie Finzel8, Reinhard Voll9, Axel Hueber10, Julie Roesch11, Eugen Feist12, José A. P. da Silva13, Arnd Doerfler11, Nemanja Damjanov14, Andreas Hess15 and Georg Schett16, 1Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, 3Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, 4Institute for Experimental Pharmacology, Erlangen, Germany, 5Insitute for Experimental Pharmacology , Fau Erlangen-Nürnberg, Erlangen, Germany, 6CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, 7Uniklinik Leipzig, Medizinische Klinik III - Bereich Rheumatologie, Leipzig, Germany, 8Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, 9Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freibrug, 10Section Rheumatology, Sozialstiftung Bamberg, Bamberg, Germany, 11Abteilung für Neuroradiologie, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, 12Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, 139.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, 14University of Belgrade Medical School, Belgrade, Serbia, 15Institute for Experimental Pharmacology, Erlangen, 16Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany

    Background/Purpose: Personalization of RA treatment is not optimal due to lack of predictors. We previously demonstrated in RA patients that central nervous system (CNS) pain…
  • Abstract Number: 1750 • ACR Convergence 2020

    Longitudinal Change in the Central Nervous System Pain Response After Treatment with Certolizumab or Placebo. a Post-hoc Analysis from the Pre-CEPRA Trial

    Juergen Rech1, Hannah Schenker2, Koray Tascilar1, Melanie Hagen2, Larissa Valor Mendez2, Verena Schoenau3, Marina Sergeeva4, Jutta Prade4, Mageshvar Sulvakumar5, Laura Konert6, Arnd Kleyer1, David Simon1, Sandra Strobelt4, Frank Behrens7, Christoph Baerwald8, Stephanie Finzel9, Reinhard Voll10, Axel Hueber11, Eugen Feist12, Julie Roesch13, José A. P. da Silva14, Arnd Doerfler13, Nemanja Damjanov15, Andreas Hess16 and Georg Schett17, 1Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, 3Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, 4Institute for Experimental Pharmacology, Erlangen, Germany, 5Insitute for Experimental Pharmacology, FAU Erlangen-Nuremberg, Erlangen, Germany, 6Institute for Experimental Pharmacology, FAU Erlangen-Nürnberg, Erlangen, 7CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, 8Uniklinik Leipzig, Medizinische Klinik III - Bereich Rheumatologie, Leipzig, Germany, 9Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, 10Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freibrug, 11Section Rheumatology, Sozialstiftung Bamberg, Bamberg, Germany, 12Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, 13Abteilung für Neuroradiologie, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, 149.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, 15Belgrade University School of Medicine, Belgrade, Serbia, 16Institute for Experimental Pharmacology, Erlangen, 17Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany

    Background/Purpose: Biologicals - bring a hope of recovery or amelioration to people suffering from RA, but only half of the patients respond to such treatment.…
  • Abstract Number: PP07 • ACR Convergence 2020

    Improving Communication with My Physician Drastically Improved My Health

    Whitney Carter1, 1Lupus and Allied Diseases Association, Inc., Pleasanton, CA

    Background/Purpose: In 2011, at the age of 14, I was sent to the emergency room with a platelet count of 19. The hematologist diagnosed me…
  • Abstract Number: 2438 • 2019 ACR/ARP Annual Meeting

    Autoantibody Mediated Salivary Gland Hypofunction in Sjögren’s Syndrome Involves Activation of Innate Immunity and Endothelial Cells

    Harini Bagavant 1, Joanna Papinska 1, Marta Trzeciak 2, Indranil Biswas 1, Nataliya Smith 2, Debra Saunders 2, Rheal Towner 2 and Umesh Deshmukh1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma City

    Background/Purpose: The presence of autoantibodies reactive against the Ro52/TRIM21 protein is a hallmark of Sjögren’s syndrome. We have reported that Ro52-immunized mice develop IgG deposits…
  • « Previous Page
  • 1
  • 2
  • 3
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology